:root { color-scheme: light dark; --frontier:#0A2835; --daylight:#F4F4F4; --linen:#DBD2C4; --catalyst:#FF6700; --slate:#46586A; --mist:#C9D4DC; --ink:#102C38; --muted:#52636c; --paper:#ffffff; --page:#eef1f2; --soft:#f7f8f8; --line:#d6dde0; --positive:#0f7058; --warning:#a64912; --shadow:0 18px 50px rgba(10,40,53,.09); --radius:18px; } @media (prefers-color-scheme: dark) { :root { --ink:#edf5f7; --muted:#b4c2c8; --paper:#102f3d; --page:#08222d; --soft:#123746; --line:#355261; --positive:#79d7bd; --warning:#ffad76; --shadow:0 18px 50px rgba(0,0,0,.28); } } *{box-sizing:border-box} html{scroll-behavior:smooth} body{ margin:0; background:var(--page); color:var(--ink); font-family:Inter, ui-sans-serif, system-ui, -apple-system, BlinkMacSystemFont, "Segoe UI", sans-serif; line-height:1.62; -webkit-font-smoothing:antialiased; } a{color:inherit;text-decoration-color:var(--catalyst);text-decoration-thickness:2px;text-underline-offset:3px} button{font:inherit} .mast{ background:var(--frontier); color:var(--daylight); border-bottom:5px solid var(--catalyst); } .language-bar{max-width:1180px;margin:auto;padding:18px 28px 0;display:flex;justify-content:flex-end} .language-toggle{display:inline-flex;border:1px solid rgba(255,255,255,.35);padding:3px;background:rgba(255,255,255,.08)} .language-toggle button{border:0;background:transparent;color:#dbe6ea;padding:7px 12px;cursor:pointer;font-size:.88rem;font-weight:700} .language-toggle button[aria-pressed="true"]{background:var(--catalyst);color:#1d150f} .language-toggle button:focus-visible{outline:2px solid #fff;outline-offset:2px} .mast-inner{max-width:1180px;margin:auto;padding:28px 28px 48px;display:grid;grid-template-columns:minmax(0,1fr) 310px;gap:56px;align-items:end} .eyebrow{font-size:.82rem;font-weight:700;letter-spacing:.11em;text-transform:uppercase;color:#ffc39e;margin:0 0 14px} h1,h2,h3{font-family:"Source Sans 3", ui-sans-serif, system-ui, sans-serif;letter-spacing:-.025em;margin:0;line-height:1.06} h1{font-size:clamp(2.55rem,6vw,5.35rem);max-width:850px;font-weight:650} .dek{font-size:1.16rem;line-height:1.55;color:#dbe6ea;max-width:790px;margin:24px 0 0} .stamp{border-top:1px solid rgba(255,255,255,.28);padding-top:16px;font-size:.85rem;line-height:1.55;color:#dbe6ea} .stamp strong{display:block;color:#fff;font-size:.98rem;margin-bottom:3px} .page{max-width:1180px;margin:0 auto;padding:0 28px 80px} .answer{ margin:-1px 0 0; display:grid; grid-template-columns:minmax(0,1.5fr) minmax(260px,.5fr); background:var(--paper); box-shadow:var(--shadow); } .answer-main{padding:42px 46px;border-right:1px solid var(--line)} .answer h2{font-size:1rem;text-transform:uppercase;letter-spacing:.08em;color:var(--catalyst);margin-bottom:15px} .answer .lead{font-family:"Source Sans 3",ui-sans-serif,system-ui,sans-serif;font-size:clamp(1.5rem,2.4vw,2.15rem);font-weight:560;line-height:1.3;max-width:800px;margin:0} .answer-side{padding:34px 30px;background:var(--soft)} .answer-side span{font-weight:750;color:var(--catalyst);font-size:2rem;display:block;line-height:1} .answer-side p{margin:10px 0 0;font-size:.96rem} .layout{display:grid;grid-template-columns:240px minmax(0,1fr);gap:56px;margin-top:54px;align-items:start} .rail{position:sticky;top:18px;font-size:.88rem} .rail-title{font-weight:750;margin-bottom:12px;color:var(--muted)} .rail a{display:block;text-decoration:none;border-left:2px solid var(--line);padding:8px 0 8px 16px;color:var(--muted)} .rail a:hover,.rail a:focus{border-left-color:var(--catalyst);color:var(--ink)} .email-card{margin-top:28px;padding:18px;background:var(--frontier);color:#f4f4f4} .email-card strong{font-family:"Source Sans 3",sans-serif;font-size:1.05rem} .email-card p{font-size:.82rem;color:#d9e3e7;line-height:1.5;margin:8px 0 14px} .copy-btn{width:100%;border:0;background:var(--catalyst);color:#1d150f;font-weight:750;padding:10px 12px;cursor:pointer} .copy-btn:hover{filter:brightness(1.07)} article{min-width:0} article h2{font-size:clamp(1.85rem,3.6vw,3rem);margin:70px 0 18px;scroll-margin-top:24px} article h2:first-child{margin-top:0} article h3{font-size:1.35rem;margin:34px 0 10px} article p{font-size:1.05rem;margin:0 0 20px} .intro{font-size:1.2rem;color:var(--muted);max-width:800px} .concepts{display:grid;grid-template-columns:repeat(3,1fr);gap:0;margin:34px 0 28px;border:1px solid var(--line)} .concept{padding:25px 22px;background:var(--paper)} .concept+.concept{border-left:1px solid var(--line)} .concept b{display:inline-grid;place-items:center;width:28px;height:28px;border-radius:50%;background:var(--catalyst);color:#15100d;margin-bottom:13px} .concept strong{display:block;font-family:"Source Sans 3",sans-serif;font-size:1.1rem;line-height:1.25;margin-bottom:8px} .concept p{font-size:.9rem;line-height:1.5;color:var(--muted);margin:0} .country-grid{display:grid;grid-template-columns:repeat(2,minmax(0,1fr));gap:12px;margin:26px 0 36px} .country{padding:18px 20px;background:var(--paper);border-top:3px solid var(--positive)} .country strong{font-family:"Source Sans 3",sans-serif;font-size:1.08rem} .country small{display:block;color:var(--muted);line-height:1.5;margin-top:4px} .country.exception{border-top-color:var(--catalyst)} .country.unverified{border-top-color:var(--warning)} .legend{display:flex;gap:18px;flex-wrap:wrap;color:var(--muted);font-size:.82rem;margin-bottom:18px} .dot{display:inline-block;width:9px;height:9px;border-radius:50%;margin-right:6px;background:var(--positive)} .dot.orange{background:var(--catalyst)}.dot.warn{background:var(--warning)} .comparison{display:grid;grid-template-columns:repeat(3,1fr);gap:14px;margin:26px 0} .lane{background:var(--paper);padding:22px;border-top:4px solid var(--mist)} .lane h3{font-size:1.22rem;margin:0 0 8px} .lane p{font-size:.9rem;color:var(--muted);margin:0} .lane.no{border-top-color:var(--warning)} .lane.yes{border-top-color:var(--catalyst)} .callout{margin:32px 0;background:var(--frontier);color:#f4f4f4;padding:28px 30px;border-left:7px solid var(--catalyst)} .callout h3{margin:0 0 10px;color:#fff} .callout p{margin:0;color:#dfe9ec} .route{display:grid;grid-template-columns:repeat(3,1fr);gap:18px;margin:30px 0} .step{padding:0 0 0 18px;border-left:4px solid var(--catalyst)} .step span{font-size:.78rem;text-transform:uppercase;letter-spacing:.1em;color:var(--muted);font-weight:750} .step strong{display:block;font-family:"Source Sans 3",sans-serif;font-size:1.18rem;line-height:1.25;margin-top:4px} .details{border:1px solid var(--line);background:var(--paper);margin:26px 0} details{border-bottom:1px solid var(--line);padding:0 22px} details:last-child{border-bottom:0} summary{cursor:pointer;font-weight:750;padding:18px 0} details p{font-size:.94rem;color:var(--muted)} .sources{font-size:.9rem;color:var(--muted);background:var(--soft);padding:24px;margin-top:54px} .sources h3{margin:0 0 12px;color:var(--ink)} .sources ul{margin:0;padding-left:20px} .sources li{margin:8px 0} .disclaimer{font-size:.8rem;color:var(--muted);border-top:1px solid var(--line);padding-top:18px;margin-top:32px} .cta{margin:58px 0 0;padding:38px;background:var(--catalyst);color:#1d150f;display:flex;justify-content:space-between;gap:32px;align-items:center} .cta h2{font-size:clamp(1.8rem,3.6vw,2.8rem);margin:0;max-width:700px} .cta p{margin:8px 0 0;max-width:650px} .cta a{background:var(--frontier);color:#fff;text-decoration:none;padding:14px 18px;font-weight:750;white-space:nowrap} .toast{position:fixed;right:20px;bottom:20px;background:var(--frontier);color:#fff;padding:12px 16px;box-shadow:var(--shadow);opacity:0;transform:translateY(10px);transition:.2s;pointer-events:none;font-size:.9rem} .toast.show{opacity:1;transform:none} @media (max-width:850px){ .language-bar{padding:14px 22px 0} .mast-inner{grid-template-columns:1fr;gap:28px;padding:22px 22px 36px} .page{padding:0 18px 56px} .answer{grid-template-columns:1fr} .answer-main{padding:30px 24px;border-right:0;border-bottom:1px solid var(--line)} .answer-side{padding:22px 24px} .layout{grid-template-columns:1fr;gap:0;margin-top:40px} .rail{position:static;margin-bottom:40px} .rail nav{display:grid;grid-template-columns:1fr 1fr} .rail a{padding:7px 12px;border-left:0;border-bottom:1px solid var(--line)} .email-card{margin-top:22px} .concepts,.comparison,.route{grid-template-columns:1fr} .concept+.concept{border-left:0;border-top:1px solid var(--line)} .country-grid{grid-template-columns:1fr} .cta{display:block;padding:28px 24px} .cta a{display:inline-block;margin-top:20px;white-space:normal} } @media (max-width:520px){ h1{font-size:2.45rem} .rail nav{grid-template-columns:1fr} article h2{margin-top:54px} } @media print{ body{background:#fff;color:#111} .mast{background:#0A2835 !important;-webkit-print-color-adjust:exact;print-color-adjust:exact} .rail,.copy-btn,.toast,.language-bar{display:none!important} .layout{display:block} .page{max-width:none} .answer{box-shadow:none} .cta{break-inside:avoid} } @media (prefers-reduced-motion:reduce){html{scroll-behavior:auto}.toast{transition:none}}
Medical-device market access · Latin America
Your NMPA approval is in hand. Does Latin America care?
A country-by-country guide to what a Chinese home-country approval actually unlocks — and where it still leaves you in the standard review queue.
Regulatory snapshot
Reviewed 16 September 2026
15-market comparison
General information, not legal advice
September 16, 2026
12
min read
By
Julio G. Martinez-Clark, CEO, bioaccess®
The short answer
Across most of Latin America, an NMPA certificate is a valid home-country document for a standard registration dossier. It does not create a faster route — no mapped market offers an established NMPA-linked shortcut.
13/15
13 markets mapped accept, or substantially appear to accept, a home-country certificate from an unrestricted issuing country. Two remain unverified.
In this analysis
Three concepts
Country view
The shortcuts
Colombia's draft
Chile's 2028 shift
Ecuador
What to do
FAQ
Add this insight to your email
Copy a concise sponsor-ready paragraph based on the article.
If you build medical devices in China, the NMPA registration certificate is the hardest document you will earn. The next question is natural: once it is in hand, does it unlock Latin America?
The answer has two layers. First, in most of the region, your NMPA certificate satisfies a standard filing requirement: it proves the device is authorized in its country of origin. Second, it buys no shortcut in almost any market. Price and schedule each country on a full-review basis unless a regulator's current text says otherwise.
Three concepts that should never be confused
1
Home-country prerequisite
A certificate proves the device is legally made or sold at home. It opens the dossier; it does not waive content.
2
Reference-country waiver
A closed list of foreign authorities may substitute for selected local dossier elements. NMPA is usually not listed.
3
Reliance or fast lane
A formal abbreviated review leans on another regulator's work. These routes are narrower still.
Where an NMPA certificate opens the standard filing route
Colombia makes the distinction especially clear. Article 29(b) of Decreto 4725 de 2005 requires an imported device to carry certification from the competent authority of its country of origin showing it is authorized for production or commercialization. The provision does not limit the origin country — so a Chinese manufacturer can use its NMPA authorization in a standard INVIMA dossier.
Standard filing document accepted
Point remains unverified
Colombia · INVIMA
NMPA certificate can satisfy the country-of-origin authorization document in a standard dossier.
Mexico · COFEPRIS
Country-of-origin free-sale certificate accepted for standard review; no NMPA reliance shortcut.
Brazil · ANVISA
Certificate required for imported class III/IV devices seeking registro; classes I/II use notificação.
Argentina · ANMAT
Imported class II–IV products use a certificate from where the device is made and/or marketed.
Chile · ISP
Chinese manufacturers can sell now through a local distributor/importer of record without NMPA, FDA, CE or another home- or reference-country authorization. For 39 listed device and IVD types, ISP registration phases in on 19 March 2028 and 19 March 2029.
Peru · DIGEMID
Certificate from the authority of the origin or exporting country, across device classes.
Ecuador · ARCSA
Ordinary ARCSA registration. The NMPA certificate works as a home-country dossier document — no established NMPA-linked lighter route.
Uruguay & Paraguay
Home-country certificate accepted without a closed reference-country restriction.
Honduras, Bolivia & Nicaragua
Home-country certificate is part of the standard dossier; no NMPA-specific fast lane identified.
Costa Rica & Panama
Substantially verified from official texts; no origin-country restriction identified.
El Salvador
Free-sale certificate required, but the issuing-country rule remains unverified.
Dominican Republic
Device-specific regulation remains draft; the exact home-country route is unverified.
The shortcuts that are not available to NMPA-only devices
Mexico
The 2025 abbreviated pathway recognizes FDA, EMA, Health Canada and TGA approvals — not NMPA.
Brazil
ANVISA's AREE optimized route uses a closed list of equivalent authorities. Verify the current annex before filing.
Colombia
Decreto 3275/2009 names the EU, US, Canada, Japan and Australia for selected dossier waivers. China is not listed.
This is the operational distinction to remember: the NMPA certificate may make a dossier eligible to file, while still leaving it on the ordinary review track.
Colombia is rewriting the rules
A Ministry of Health draft decree notified to the WTO in May 2026 would replace the device regime, repealing Decreto 4725/2005, Decreto 3275/2009 and nine other decrees. It remains a proposal and would take effect 18 months after publication.
The direction of travel
The home-country certificate survives, the old reference-country waiver disappears, and a new optimized analysis procedure — PAO — is proposed for high- and very-high-risk devices.
1. The home-country route survives
Draft Article 53(d) keeps a free-sale certificate issued by the competent authority of the country of origin or a country where the device is marketed. Draft Article 50 modernizes the mechanics: online verification may replace an apostilled paper copy, while undated certificates must have been issued within two years.
2. The old waiver disappears
Decreto 3275/2009 would be expressly repealed. The draft does not replace its dossier-trim mechanism for lower-risk devices.
3. A new PAO reliance lane appears
Draft Articles 79–86 create a Procedimiento de Análisis Optimizado for high- and very-high-risk devices. Listed authorities include TGA, Health Canada, FDA, MHLW/PMDA, ANVISA, EU authorities and MHRA. NMPA is not on the list.
One commercially important detail: an ordinary ANVISA authorization could become an onward reliance asset for Colombia. That strengthens the logic of building evidence and KOL support in Brazil when Brazil is a target market. The PAO remains discretionary, and a foreign authorization obtained through an abbreviated procedure may be excluded.
Chile is open now — but the ISP clock is running
Under Chile’s current model, a Chinese manufacturer can begin selling now through a Chilean distributor/importer of record. Before the applicable transition deadline, this route does not require a home-country or reference-country authorization: no NMPA certificate, FDA clearance or approval, CE mark, or equivalent foreign approval is needed to enter the market.
Chile published Exempt Decree No. 25 on 19 March 2026, bringing 39 numbered medical-device and in vitro diagnostic types into the mandatory sanitary-control regime in two waves. The first 13 categories become mandatory on 19 March 2028; they include cardiovascular implants and catheters, heart valves, cochlear implants, orthopedic and soft-tissue implants, copper IUDs, insulin pumps and accessories, and blood bags.
Sell now, start the ISP file now
A second group follows on 19 March 2029, covering imaging, radiotherapy, dialysis, ventilation, extracorporeal-circulation, electrosurgical, ophthalmic, continuous-glucose-monitoring, CPAP/BPAP and sterilization equipment, oncology software and several IVD categories. Market entry during the transition should run in parallel with the applicable ISP file.
ISP has up to 12 months from publication to issue the technical instruction for conformity verification. Because voluntary verification can begin only after that instruction appears, the practical preparation window for the first wave may be closer to one year than two.
After each transition deadline, a covered device can be manufactured, imported, marketed or distributed only with the required ISP conformity verification or sanitary registration. Manufacturers should prepare technical documentation, Spanish-language labels and instructions, local regulatory ownership, traceability and postmarket/technovigilance systems now.
An NMPA or other foreign authorization may still support a future Chilean dossier, but it is not a prerequisite for today’s distributor/importer-of-record route and does not create a reliance shortcut. The reform is phased and applies to the listed categories; it does not place every medical device under immediate mandatory registration.
Ecuador
Ecuador follows the region's standard pattern: the NMPA certificate can serve as the home-country authorization document in an ordinary ARCSA registration dossier, but there is no established NMPA-linked lighter review. Price and schedule Ecuador on a full-review basis, like the other mapped markets.
Correction (16 September 2026): an earlier version of this analysis described Ecuador's homologation route as an NMPA-linked shortcut. The corrected position is ordinary ARCSA registration.
What should a Chinese manufacturer do?
If no reliance shortcut exists, do not wait for one. Lead with evidence and sequence the region around the markets that matter commercially.
Route 1
Fast FIH start
Costa Rica, El Salvador, Chile or Panama when speed is the primary objective.
Route 2
Brazil-first evidence
If Brazil is a target market, run FIH there for early KOL engagement and ANVISA-ready regional data.
Route 3
Registration sequence
Use the NMPA certificate as the standard home-country document, then file market by market with regional evidence.
The picture changes when you add FDA clearance, a CE mark, a Health Canada licence or a Japan approval. Those reference-market authorizations can activate lighter routes in Mexico, Brazil and Colombia that an NMPA-only dossier cannot use.
Frequently asked questions
Does NMPA approval let a device register in Colombia?
Yes, as the qualifying country-of-origin authorization document in a standard INVIMA dossier. It does not currently create a reliance shortcut or guarantee approval.
Which LATAM country explicitly recognizes China for a lighter device review?
None of the 15 mapped markets. Ecuador requires ordinary ARCSA registration — the NMPA certificate works as a home-country dossier document, not a fast lane.
Will Colombia's proposed 2026 decree recognize NMPA under the PAO?
Not as drafted. The proposed PAO list names several authorities, including ANVISA, but not NMPA. The draft is not yet law.
Should a manufacturer wait for FDA or CE approval before entering LATAM?
Not necessarily. An evidence-first LATAM strategy can create regional clinical data now; later reference-market approvals may unlock additional abbreviated routes.
Regulatory anchors
- Colombia — Decreto 4725 de 2005, especially Article 29(b).
- Colombia — Decreto 3275 de 2009 and the May 2026 WTO-notified draft decree.
- Mexico — Reglamento de Insumos para la Salud, Article 180, and the 2025 abbreviated pathway.
- Brazil — RDC 751/2022 and IN 290/2024.
- Argentina — Disposición 2318/2002; Peru — D.S. 016-2011-SA.
- Chile’s Easy Market Ends In 2028 — analysis of Exempt Decree No. 25 and the 2028/2029 transition.
This regulatory snapshot reflects the instruments reviewed as of 16 September 2026. El Salvador and the Dominican Republic remain unverified on the points noted. Regulators revise lists, annexes and filing practice; verify the current official text before making a filing decision. General information only, not legal advice.
Sequence the evidence first. Then register in the right order.
bioaccess helps medical-device teams build first-in-human and market-entry programs across Latin America around the evidence they already have — and the approvals they still need.
Discuss your market sequence
Talk to bioaccess